Compare Alcon AG (ALC) vs MasterCard Inc (MA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alcon AG vs MasterCard Inc — how do they compare? Alcon AG trades at $66.81 (market cap $32.69B), while MasterCard Inc trades at $519.08 (market cap $469.73B). The key difference: MasterCard Inc is far larger — about 14.4× Alcon AG's market cap, and MasterCard Inc pays the higher dividend (0.65%). Which is the better fit depends on your goals.
| ALC | MA | |
|---|---|---|
Market Cap | $32.69B | $469.73B |
Sector | Health | Consumer Cyclical |
52-Week High | $92.22 | $598.96 |
52-Week Low | $62.02 | $471.55 |
Enterprise Value | $36.28B | $480.47B |
Dividend Yield | 0.54% | 0.65% |
Volume | — | 4,635,698 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
Mastercard (MA) trades at $517.78, down 2.87% on the day, amid a bullish technical outlook and strong fundamentals. The stock shows robust revenue growth, with 2025 revenue reaching $32.79B and net income of $14.97B, supported by high profitability margins. Recent earnings beats and a consensus analyst price target of $637.67 highlight positive sentiment, though elevated valuation ratios like a P/E of 30.77 warrant caution.
Outlook remains favorable with continued earnings growth and institutional accumulation, but risks include competitive disruption from new payment technologies and high valuation multiples. The stock's current price near key support at $514 suggests potential for rebound if fundamentals hold.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →About MasterCard Inc
Mastercard Incorporated provides financial transaction processing services. The Company offers payment processing services for credit and debit cards, electronic cash, automated teller machines, and travelers checks. Mastercard serves customers worldwide.
Read more on MA →
